Jim Simons Bellus Health Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$7.14 - $8.53 $640,008 - $764,603	89,637 Added 44.65%	290,375 $2.09 Million
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $1.65 Million - $2.16 Million	200,738 New	200,738 $1.65 Million
Q2 2022 Aug 12, 2022	SELL	$6.46 - $10.02 $921,913 - $1.43 Million	-142,711 Reduced 68.73%	64,938 $598,000
Q1 2022 May 13, 2022	BUY	$5.56 - $7.99 $995,301 - $1.43 Million	179,011 Added 625.08%	207,649 $1.44 Million
Q4 2021 Feb 11, 2022	BUY	$5.26 - $8.3 $150,635 - $237,695	28,638 New	28,638 $230,000
Q1 2021 May 13, 2021	SELL	$3.03 - $4.58 $170,892 - $258,312	-56,400 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$2.27 - $3.3 $128,028 - $186,120	56,400 New	56,400 $173,000
Q3 2020 Nov 13, 2020	SELL	$2.14 - $12.02 $140,037 - $786,564	-65,438 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$8.88 - $11.15 $47,410 - $59,529	5,339 Added 8.88%	65,438 $677,000
Q1 2020 May 14, 2020	SELL	$5.77 - $10.85 $130,050 - $244,548	-22,539 Reduced 27.27%	60,099 $597,000
Q4 2019 Feb 13, 2020	BUY	$5.76 - $7.6 $254,592 - $335,920	44,200 Added 114.99%	82,638 $627,000
Q3 2019 Nov 13, 2019	BUY	$6.24 - $8.84 $239,853 - $339,791	38,438 New	38,438 $247,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.